We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals

40 hedge funds and large institutions have $5.79M invested in Actinium Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more capital inflows, than outflows

Capital inflows: $854K | Capital outflows: $472K

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

1.01% more ownership

Funds ownership: 14.45% → 15.46% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 44 → 40 (-4)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Holders
40
Holders Change
-4
Holders Change %
-9.09%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
8
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ATNM Hedge Fund Activity: Q3 2019 in Review

40 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2019, worth a combined $5.79M — up 0.26% from $5.77M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ATNM and 3 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $376K. The largest seller was Endurant Capital Management, cutting an estimated $262K.

  • 40 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2019, down from 44 in Q2 2019.
  • Funds reported $5.79M of Actinium Pharmaceuticals stock for Q3 2019, up 0.26% quarter-over-quarter.
  • 3 funds opened new Actinium Pharmaceuticals positions in Q3 2019 and 7 closed out, a net change of -4 holders.
  • The largest Actinium Pharmaceuticals buyer in Q3 2019 was Vanguard Group, an estimated $376K added.
  • The largest Actinium Pharmaceuticals seller in Q3 2019 was Endurant Capital Management, an estimated $262K sold.

Based on aggregated 13F filings for Q3 2019.